In December 2017, the Boston radio station WBUR chronicled the case of the first patient at Massachusetts General Hospital to receive axicabtagene ciloleucel (Yescarta, Gilead) outside a clinical trial. The chimeric antigen receptor T cells (CAR-Ts) were made from 71-year-old Barbara Kearney’s own…
National Coverage Analysis of CAR-T Therapies — Policy, Evidence, and Payment
